Institute for Cancer Genetics and Informatics, Oslo University Hospital

"TLS-positive patients had a lower risk of recurrence, especially in tumors with MMR deficiency", said our skilled pathologist, Dr Manohar Pradhan, when he presented research on the prognostic value of tertiary lymphoid structures (TLS) in endometrial carcinoma. The study involves 1,228 patients at Oslo University Hospital, and is a collaboration with the Department of Gynecological Oncology, OUS. Dr. Pradhans's session was one of 184 featured at the 36th European Congress of Pathology (ECP), which attracted over 5,700 participants from 100 countries. Among them, a delegation from our institute appreciated the opportunity to contribute to and learn from the ongoing advancements within the field of pathology. ECP was arranged in Florence 7 - 11 September 2024. We look forward to seeing how insights presented at this year's ECP will contribute to future research and clinical practice.    Manohar Pradhan, Wanja Kildal , Kristina Lindemann , Kari Anne Tobin . Gunnar Kristensen , Hanne Askautrud #Pathology #ECP2024 #EndometrialCarcinoma #CancerResearch  Oslo University Hospital European Society of Pathology

Thanks to 558 brave prostate cancer patients from Vestfold county, Dr. Erik Skaaheim Haug (Sykehuset i Vestfold) and Dr. Karolina Cyll (Oslo University Hospital) have completed a study funded by Helse Sør-Øst. Their findings, which leverage data from these men's cancer journeys, have just been published in the prestigious British Journal of Cancer. This achievement underscores the power of patient participation in advancing medical knowledge and improving cancer care. A heartfelt thank you to all involved! #ProstateCancerResearch Oslo universitetssykehus Sykehuset i Vestfold HF Prostatakreftforeningen https://lnkd.in/damicxTU

In our latest article, Wanja Kildal et al. demonstrate the potential of deep learning models to accurately detect protein expression in immunohistochemically stained tissue samples across multiple cancer types. The study developed models for nuclear, cytoplasmic, and membranous staining patterns, achieving high accuracy rates compared to manual scoring. Importantly, the AI-driven approach showed a prognostic value similar to that of manual scoring in survival analyses. This breakthrough could enhance efficiency and reproducibility in cancer diagnostics and research. #ous, #immunohistochemistry, #cancer

A new project suggests to use artificial intelligence to improve cancer prevention and treatment in Norway. The project will pioneer multi-agent, multimodal AI platforms designed for predicting future events based on sequences of past occurrences. It involves developing a foundation model for cancer medicine, leveraging extensive hospital records, national cancer registries, public databases, and scientific publications. This foundation model will be capable of considering the impact of medical actions on patients, the healthcare system, and society, even when data is incomplete or multimodal. The proposal was recently submitted to Norges forskningsråd, by Oslo Cancer Cluster and a wide network of national and international partners. UiT- The Arctic University of Norway : @Therese H. Nøst, Tonje Braaten, Torkjel Sandanger Cancer Registry of Norway (Kreftregisteret): Jan F. Nygård, Solveig Hofvind Oslo Cancer Cluster: Ketil Widerberg Vestre Viken HF: Kristine Kleivi Sahlberg Norwegian University of Science and Technology (NTNU): Mette Langaas, Thea Bjørnland, Pål Sætrom, Åsmund Flobak University of Bergen (UiB): Leif Oltedal @University of Magdeburg: Alexander Binder University of Oslo: Arnoldo FRIGESSI, Jim Tørresen, Jon Michael Gran, Kai Olav Ellefsen, Kjetil Røysland, @Magne Thoresen, Manuela Zucknick, Ole Christian Lingjærde, Valeria Vitelli University of Oxford: David Kerr University of Cambridge: @Sylvia Richardson Kreftforeningen Oslo University Hospital: @Andreas Kleppe, Eivind Hovig, Gunhild Mari Mælandsmo, Inger Nina Farstad, Karsten Rydén-Eilertsen, Kjetil Tasken, Mads Haugland Haugen, @Ole-Johan Skrede, @Olivier Boissou, Sigbjørn Smeland, Tarjei S. Hveem, Tero Aittokallio, Torje Vegar Pedersen, Vessela Kristensen, Åslaug Helland https://lnkd.in/dkX-SEQB

Congratulations to Andreas Kleppe, who last Friday received the prestigious Early Career Award from Oslo University Hospital. His unwavering dedication, attention to detail, and ability to motivate others makes him a highly valued colleague.  We would also like to congratulate Kjetil Taskén, who was awarded the Excellent Researcher Award, and Chloe Steen (also) for the Early Career Award

We are grateful to the European Society of Digital and Integrative Pathology - ESDIP for giving us the opportunity to present our project, "Predicting Prostate Cancer Outcome from Histopathology Section Images Using Deep Learning," at this year's European Congress on Digital Pathology 2024 (ECDP). Our designated speaker, Mr. Anthony Manet, steadily shared our findings with top experts, researchers, and industry professionals who have gathered in the beautiful city of Vilnius to explore the latest advancements in digital pathology. Download the abstracts (and program) here: https://lnkd.in/dMR4xun7 Oslo University Hospital DoMore Diagnostics Sykehuset i Vestfold HF UiT- The Arctic University of Norway The Faculty of Mathematics and Natural Sciences Universitetssykehuset Nord-Norge Nuffield Department of Clinical Neurosciences, University of Oxford

Vi er veldig glade for Europeisk storsatsing innen kreft og for at vi er sentral i to av de store prosjektene; EUnetCCC og JANE2. OUS sin bit av kaka er henholdsvis 110 og 30 millioner kroner 👏👏👏 💬 -Dette er bra, det er store beløp som illustrerer omfanget og OUS som en sentral aktør i et omfattende Europeisk samarbeid, sier klinikkleder Sigbjørn Smeland om OUS sin tildelte rolle i EUnetCCC. 💬 - Tilsvarende vil også det andre Joint Action programmet, JANE 2 , bli finansiert og med OUS i sentrale roller. Vi mener dette tydeliggjør OUS sin posisjon som et ledende kreftsenter ikke bare i Norge, men også i Europa, sier Smeland. Prosjektet er en del av EUs kreftsatsing, Europe Beating Cancer. Oslo universitetssykehus skal lede den største arbeidspakken i prosjektet. Alle EUs 27 medlemsland og fire assosierte land er involvert, med totalt 159 partnere. Dette er den største samarbeidsprosjektet mellom kreftsentrene i Europa hittil. Prosjektet er ment å gå over til å bli et varig nettverk for europeiske kreftsentre. 💬 - Dette gir Oslo universitetssykehus en unik mulighet til å påvirke etableringen av nettverket, samarbeidsmønstret innen kreft i Europa og å utvikle vårt eget nettverk. Når Helse- og omsorgsdepartementet har pekt på oss som representant for Norge, ligger det en forpliktelse til å trekke kreftsentrene i de andre regionsykehusene med i samarbeidet. Det forutsettes at regionsykehusene etablerer CCC nettverk i sin region. Dette vil styrke samarbeidet på kreftområdet i Norge, sier Smeland. #Kreft #Kreftsammarbeid #EUnetCCC #JANE2

We are happy to announce that Ole-Johan Skrede successfully defended his thesis "Selected studies on the application of histological image analysis in cancer diagnostics using deep learning" for the degree of Philosophiae Doctor, today 26 April 2024! Cinicians and cancer patients will benefit from the doctoral work of Dr. Ole-Johan Skrede and the methods he has helped develop. We are so proud! Congratulations! 👏💐 Oslo universitetssykehus Det matematisk-naturvitenskapelige fakultet (UiO)

We are thrilled to announce that our esteemed colleague Ole-Johan Skrede is set to defend his doctoral thesis on Friday, April 26th. His thesis titled "Selected Studies on the Application of Histological Image Analysis in Cancer Diagnostics Using Deep Learning" delves into the ways in which artificial intelligence can transform cancer diagnostics. We are looking forward to seeing you there! https://lnkd.in/djSwizpm

Congratulations to all women! Our emloyees Wanja Kildal and Hanne Askautrud celebrated International Women’s Day with a poster presentation on endometrial cancer at #ESGO in Barcelona with long-term collaborator Kristina Lindemann. #ESGO #endometrialcancer Oslo universitetssykehus